Supportive Oligonucleotide Therapy (SOT) Background
Supportive Oligonucelotide Therapy (SOT) is a new treatment for Lyme disease. SOT is also called Antisense Oligonucelotide Therapy (ASOT) which is the term used in medical research papers. SOT uses laboratory derived nucleic acids (genetic code) that blocks production of disease causing proteins or even gene expression. These pieces of genetic code are called oligonucleotides. You can think of oligonucleotides as a genetic message.
For example, in Duchenne Muscular Dystrophy (DMD), SOT provides oligonucleotides that direct the correct production of a protein called dystrophin. People with muscular dystrophy are born with DNA that provides the wrong genetic message for dystrophin. SOT correction to the DNA message leads to production of dystrophin. This prevents the muscle damage seen in DMD.
In Lyme disease, a currently available type of SOT produced by RGCC in Greece uses oligonucleotides intended to stop germ growth and replication. Unlike the SOT therapy for Duchenne muscular dystrophy, the Lyme SOT is not a US Food and Drug Administration (FDA) approved drug. To be approved by the FDA, a therapy must have scientific evidence of safety and effectiveness. (See link for article)
Dr. Ross is unsure if SOT for Lyme/MSIDS works, and that some of his patients using it before seeing him experienced little to no effects, but some of his colleagues state some patients have experienced improvement. He also reminds readers that there is a placebo effect of 35% on average in clinical trials for drugs.